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Abstract
Background:While residual plasma viremia is commonly observed in HIV-infected
patients undergoing antiretroviral treatment (ART), little is known about its
subclinical consequences.
Methods: This cross-sectional study included 47 male, never-smoking, non-diabetic
patients with >4 years of ARTand controlled HIV-replication (HIV-viral load, VL ,20
copies/mL for>1 year). Residual HIV-VL wasmeasured using an ultrasensitive assay
(quantification limit: 1 copy/ml). Patients were categorized as having detectable
(D; 1-20 copies/mL, n514) or undetectable (UD;,1 copies/mL, n533) HIV-VL. Linear
regression was used to model the difference in total carotid intima-media thickness
[c-IMT, measures averaged across common carotid artery (cca), bifurcation, and
internal carotid artery] and cca-IMT alone across detection groups. Multivariable
models were constructed for each endpoint in a forward-stepwise approach.
OPEN ACCESS
Citation: Boyd A, Meynard J-L, Morand-Joubert L,
Michon A, Boccara F, et al. (2014) Association of
Residual Plasma Viremia and Intima-Media
Thickness in Antiretroviral-Treated Patients with
Controlled Human Immunodeficiency Virus
Infection. PLoS ONE 9(11): e113876. doi:10.1371/
journal.pone.0113876
Editor: Cristian Apetrei, University of Pittsburgh
Center for Vaccine Research, United States of
America
Received: June 24, 2014
Accepted: October 8, 2014
Published: November 21, 2014
Copyright:  2014 Boyd et al. This is an open-
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and repro-
duction in any medium, provided the original author
and source are credited.
Data Availability: The authors confirm that, for
approved reasons, some access restrictions apply
to the data underlying the findings. The data cannot
be publicly available due to legal and ethical
restrictions from the French Authority (Commission
nationale de l’informatique et des liberte´s). Data
are from the ANRS EP42 CHIC study. Requests for
data use can be made to the Scientific Manager of
the study (Moı¨se Desvarieux at md108@cumc.
columbia.edu) or a representative from the Agence
nationale de recherche sur le sida et les he´patites
virales (Sandrine Couffin-Cadiergues at sandrine.
couffin-cadiergues@anrs.fr).
Funding: This study was funded by the Agence
Nationale de Recherche sur le Sida et les
He´patites (ANRS grant 2007/303 to MD) and
Sidaction (grant AI 20). AB was awarded a post-
doctoral fellowship from the Agence nationale de
recherche sur le sida et les he´patites virales. MD is
also the recipient of a Chair in Chronic Disease
from the E´cole des Hautes Etudes en Sante´
Publique, France. This collaboration was rendered
possible by a Contrat d’Interface (to MD) between
INSERM and Hoˆpital Saint-Antoine. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: FB reports receiving
research grants from Boehringer-Ingelheim and
Gilead Sciences. All other authors report having no
association, be it commercial or other, that might
pose a conflict of interest.
PLOS ONE | DOI:10.1371/journal.pone.0113876 November 21, 2014 1 / 12
Results: No significant differences were observed between viremia groups with
respect to median ART-duration (9.6 years, IQR56.8–10.9), nadir CD4+T-cell (208/
mm3, IQR5143–378), and CD4+T-cell count (555/mm3, IQR5458–707). Median
adjusted inflammatory markers tended to be higher in patients with D- than UD-
viremia, with differences in IL-10 being significant (p50.03). After adjustment on
age, systolic blood pressure, and insulin resistance, mean cca-IMT was
significantly lower in patients with undetectable (0.668 mm¡0.010) versus
detectable viremia (0.727 mm¡0.015, p50.002). Cca-IMT was also independently
associated with age and insulin resistance. Mean adjusted total c-IMT was no
different between viremia groups (p50.2), however there was large variability in
bifurcation c-IMT measurements.
Conclusions: Higher cca-IMT was observed in patients with detectable, compared
to undetectable, HIV-VL in never-smoking ART-controlled patients, suggesting that
residual HIV viremia may be linked to atherosclerosis.
Introduction
Among HIV-1-infected patients, antiretroviral therapy (ART) typically leads to
the suppression of HIV-replication below the quantification limit of many
conventional techniques. Even though these patients would be considered as
having controlled HIV viral load (usually at ,50 copies/mL), roughly two-thirds
continue to exhibit residual viremia between 1–50 copies/mL during long-term
ART. [1–4] The consequences of residual viremia are poorly understood and
while several recent studies have examined the effect of residual viremia on
various inflammatory markers [3, 5], these findings have rarely extended to the
subclinical or clinical level. [6]
We have previously reported a strong association between increased carotid
intima media thickness (c-IMT) and known HIV-duration, regardless of ART,
implying that c-IMT could still be increasing during infection despite control of
HIV-replication. [7] Residual viremia and alteration in inflammatory cytokines
and/or chemokines could be potential explanations for this observation. We thus
aimed to compare a number of pro-inflammatory and anti-inflammatory
markers, chemokines, and c-IMT in an antiretroviral-treated population of non-
smoking, male patients according to levels of residual viremia.
Materials and Methods
Study design
The Collaboration on HIV, Inflammation and Cardiovascular Disease study was
specifically designed to study the impact of treatment versus HIV on subclinical
vascular disease. [7] Inclusion criteria were heavily restricted as to reduce
Residual Plasma HIV Viremia and c-IMT
PLOS ONE | DOI:10.1371/journal.pone.0113876 November 21, 2014 2 / 12
confounding by specifically smoking and gender. Briefly, fifty age-matched (¡5
years) triads (n5150) of never-smoking, male subjects were enrolled in three
groups: a) HIV-infected patients .35 years old, undergoing ART for >4 years,
and with HIV-1 RNA viral load ,400 copies/mL; b) HIV-infected patients for >2
years, ART-nai¨ve and not meeting the indication for ART-initiation; and c) HIV-
negative as confirmed by serology. All patients were recruited from Saint-Antoine
Hospital (Paris, France) between March 2008-June 2009 and provided written
informed consent. The protocol was approved by the Hoˆtel-Dieu Hospital Ethics
Committee (Paris, France).
For this sub-study, we decided to primarily focus on ART-treated patients with
undetectable HIV replication based on standard techniques. Only the 50 ART-
treated patients from group (a) were therefore included. Among them, three
patients were additionally excluded because they had an HIV-VL between 20-400
copies/mL. In total, 47 patients were included in present analysis.
Quantification of biochemical and virological parameters
HIV-VL was measured using an adapted Cobas AmpliPrep/Cobas TaqMan HIV-1
assay (Roche Diagnostics, Meylan, France; quantification limit: 1 copy/ml). [7]
Patients were defined as having either detectable (D; 1–20 copies/mL, n514) or
undetectable (UD; ,1 copies/mL, n533) levels of HIV-viremia.
Inflammatory markers and chemokines were selected for their specific role in
HIV-infection [7] and quantified from serum samples stored at 280 C˚.
Interleukin (IL)-6, IL-18, IL-10, IL-27 (Bender Medsystems, Burlingame, CA,
USA), resistin (R&D Systems, Minneapolis, MN, USA), total and high molecular
weight (HMW) adiponectin (Bu¨hlman, Du¨sseldorf, Germany) levels were
analyzed using an enzyme-linked immunosorbent assay. Serum high-sensitivity
C-reactive protein (hs-CRP) and serum amyloid-A (SSA) were measured by
immononephelometry on an IMMAGE analyzer (Beckman-Coulter, Miami, FL,
USA). Plasma D-dimer was measured by enzyme linked fluorescent assay on a
VIDAS analyzer (Biome´rieux, Marcy-l9Etoile, France). Chemokines were
quantified from plasma using the BD Cytometric Bead Array system (BD,
Franklin Lakes, NJ, USA).
Assessing c-IMT and hypertension
c-IMT scanning and reading protocols have been detailed elsewhere. [7, 8] Total
c-IMT was calculated as a composite measure (mean of 12 sites), combining near
and far wall of the common carotid artery (cca)-IMT, bifurcation c-IMT, and
internal carotid artery (ica)-IMT, bilaterally. Measures with the highest variability
were bifurcation c-IMT (SD50.106, 75th-25th%tile50.130), followed by cca-IMT
(SD50.082, 75th-25th%tile50.093) and ica-IMT (SD50.071, 75th-
25th%tile50.100). Hypertension was defined by prior physician9s diagnosis,
systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg, or the
use of antihypertensive drugs.
Residual Plasma HIV Viremia and c-IMT
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Statistical analysis
In order to be consistent with previous analyses [7], median pro-/anti-inflammatory
markers and chemokines were adjusted a priori by age, hypertension, and duration
of ART using quantile regression. Adjusted median levels were compared between D
and UD groups using a two-tailed t-test based on estimated variance. [9]
Linear regression was used to model the mean difference in total c-IMT and
cca-IMT levels comparing D versus UD groups (D). Univariate models were
constructed to estimate the mean difference in total c-IMT and cca-IMT levels
across various risk-factors. A multivariable model was constructed using a
predictive approach, while forcing viremia group in the model and including risk-
factors with a p,0.05 from univariate analyses in a forward-stepwise manner. In
order to avoid model overfitting, we evaluated the addition of each covariable
using the Bayesian Information Criteria, which penalizes model complexity by the
number of observations. After fitting the full multivariable model, other HIV and
metabolic risk factors were added individually to the full model so that residual
confounding could be assessed. Multivariable models were also constructed for
the bifurcation c-IMT and ica-IMT segments, however residual confounding was
not assessed. All statistics were performed using STATA (v12.1, College Station,
TX, USA).
Results
Patient characteristics are described in Table 1, while stratified on viremia group.
Patients were at low-risk of cardiovascular disease (CVD) [median (IQR) D:A:D
score [10] of 10-year CVD-risk: 3.2% (2.6%–5.6%)], while three patients had
concomitant statin-use. Three patients had BMI .30 kg/m2 and no patients were
diagnosed with glucose intolerance or diabetes.
Inflammatory markers and residual-viremia
Median adjusted pro-inflammatory markers tended to be higher in patients with
D- than UD-viremia (hs-CRP: 3.11 vs 2.43 mg/l; IL-18: 213.8 vs 89.7 pg/mL;
resistin: 6.48 vs 6.25 ng/ml; IL-6: 1.33 vs 0.79 pg/mL; D-Dimer: 147.4 vs 139.3 ng/
ml, respectively) as was insulinemia (7.3 vs 6.0 mU/l), although no significant
differences were observed (Table 2). Likewise, patients with D-viremia exhibited
higher adjusted median levels of anti-inflammatory markers than with UD-
viremia (HMW/total adiponectin: 1.06/3.61 vs 0.92/2.54 mg/ml; IL-27: 1325 vs
1111 pg/mL; IL-10: 0.94 vs 0.65 pg/mL, respectively), with only differences in IL-
10 being significant (p50.03). In addition, no significant difference in chemokines
were observed between groups, yet Mig was roughly 1.5-times higher and
fractalkine 2-times higher in patients with D- vs. UD-viremia.
Residual Plasma HIV Viremia and c-IMT
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Carotid-IMT and residual viremia
As shown in Table 3, mean total c-IMT was significantly different between D and
UD groups in univariate analysis. However, after adjusting on age and HOMA-IR
Table 1. Demographic and HIV characteristics between viremia groups.
D-viremia UD-viremia
(n514) (n533) p*
General characteristics
Age, years{ 41 (37–48) 40 (37–43) 0.2
BMI, kg/m2{ 23 (21–24) 22 (21–25) 0.8
Hypertension** 2 (14.3) 1 (3.0) 0.2
Total cholesterol mmol/L{{ 5.05 (4.48–5.28) 4.68 (4.21–5.70) 0.5
HDL cholesterol mmol/L{{ 1.20 (0.79–1.37) 1.09 (0.95–1.31) 0.4
LDL cholesterol mmol/L{{ 3.10 (2.74–3.29) 3.19 (2.60–3.91) 0.8
Triglycerides mmol/L{{ 1.63 (0.81–2.44) 1.19 (0.92–2.03) 0.3
Fasting glucose mmol/L{{ 4.52 (4.07–5.00) 4.53 (4.28–4.97) 0.9
HOMA-IR{{ 1.69 (1.20–2.33) 1.41 (1.07–1.91) 0.2
QUICKI{{ 0.355 (0.344–0.371) 0.365 (0.350–0.384) 0.5
HIV Infection
Duration of HIV infection, years{ 13.0 (7.9–17.0) 10.4 (7.6–15.1) 0.5
Duration of ART, years{ 10.5 (5.2–11.4) 9.5 (7.1–10.5) 0.8
CD4+ count, cells/mm3{ 475 (420–771) 557 (508–703) 0.5
Nadir CD4+ count{ 147 (88–364) 254 (170–378) 0.2
CD8:CD4 ratio{ 1.20 (0.91–1.57) 1.31 (0.89–1.57) 0.9
HIV-RNA, copies/mL{ 6 (3–10) 0 ntp
Years from last HIV-VL .50{ 3.4 (1.4–5.0) 4.1 (2.1–6.3) 0.5
D-viremia UD-viremia
(n514) (n533) p*
Antiretroviral medication
Treatment with NRTI** 13 (92.9) 32 (97.0) 0.5
Duration of NRTI treatment{ 147.9 (91.7–199.6) 124.7 (79.1–193.1) 0.4
Treatment with NNRTI** 6 (42.9) 17 (51.5) 0.6
Duration of NNRTI treatment{ 67.1 (18.5–109.7) 100.4 (81.4–115.6) 0.3
Treatment with PI** 9 (64.3) 12 (36.4) 0.1
Duration of PI treatment{ 107.3 (95.9–127.9) 77.1 (59.7–134.0) 0.3
Treatment with raltegravir** 2 (14.3) 0 0.08
All patients were male, non smokers.
*Significance determined using a Kruskal-Wallis equality-of-populations rank test for continuous variables and Pearson x2 test or Fisher’s Exact test for
categorical variables;
**number (%);
{median (25-75th%tile).
{{Medians (25th and 75th %tiles) adjusted by age, hypertension, and duration of ART using quantile regression. Significance determined using a two-tailed t-
test based on variance estimations.
D – detectable; UD – undetectable; HDL – high-density lipid; LDL – low-density lipid; HOMA-IR – homeostatic model assessment of insulin resistance;
QUICKI – quantitative insulin sensitivity check index; HIV – human immunodeficiency virus; ART – antiretroviral therapy; cp/mL – copies/mL; VL – viral load;
NRTI – nucleos(-t)ide reverse transcriptase inhibitor; NNRTI – non-nucleos(-t)ide reverse transcriptase inhibitor; PI – protease inhibitor; ntp – no test
performed.
doi:10.1371/journal.pone.0113876.t001
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(both of which were independently associated with total c-IMT), there was no
significant difference between viremia groups (mean¡SE, D: 0.768 mm¡0.014
versus UD: 0.746 mm¡0.009, p50.2). In further analysis, the difference between
viremia groups remained non-significant after separately and additionally
adjusting (to the full multivariable model) for years undergoing ART
(D50.024 mm, p50.14), years of known HIV-infection (D50.022 mm, p50.19),
years of undetectable HIV-viremia from most recent HIV-VL .50 copies/mL
(D50.021 mm, p50.2), nadir CD4+ cell count (D50.028, p50.11), or protease
inhibitor (PI)-use (D50.022 mm, p50.2). The following CVD risk factors were
also added separately to the full multivariable model, showing no significant
Table 2. Description of pro- and anti-inflammatory markers between viremia groups.
D-viremia UD-viremia
(n514) (n533) p*
Pro-inflammatory
Hs-CRP mg/l 3.11 (0.59–4.82) 2.43 (0.65–5.14) 0.5
Resistin ng/ml 6.48 (5.06–8.06) 6.25 (4.40–8.66) 0.9
IL-18** pg/mL 213.8 (134.3–305.7) 89.7 (4.5–180.3) 0.06
IL-6** pg/mL 1.33 (0.79–1.57) 0.79 (0.37–1.21) 0.2
D-Dimer ng/ml 147.4 (108.0–226.5) 139.3 (113.4–177.7) 0.8
Insulin mU/l 7.35 (5.17–9.14) 6.04 (5.03–10.21) 0.4
Serum Amyloid A** mg/l 5.1 (5.1–10.3) 5.1 (5.1–8.4) ntp
Anti-inflammatory
Total adiponectin mg/ml 3.61 (2.07–5.86) 2.54 (1.48–3.61) 0.07
HMW adinopectin mg/ml 1.06 (0.86–2.46) 0.92 (0.69–1.51) 0.7
IL-27** pg/mL 1325 (638–2872) 1111 (430–2287) 0.6
IL-10** pg/mL 0.94 (0.69–1.55) 0.65 (0.41–0.82) 0.03
Chemokines
ICAM-1 pg/mL 128589 (10010–145134) 121905 (100908–128912) 0.6
I-TAC pg/mL 257.5 (108.8–339.8) 254.7 (153.7–350.6) 0.9
IP-10 pg/mL 214.1 (168.8–354.7) 237.4 (164.3–415.8) 0.6
Fractalin** pg/mL 82.1 (11.2–415.3) 41.4 (11.2–264.1) 0.5
VCAM-1 pg/mL 129635 (121514–189670) 141891 (117047–164106) 0.6
Mig pg/mL 376 (270–797) 261 (152–794) 0.3
MCP-1 pg/mL 76.9 (31.6–103.4) 51.7 (35.3–77.5) 0.2
E-selectin pg/mL 10344 (8131–33045) 11787 (4928–23219) 0.7
P-selectin pg/mL 125138 (87195–164171) 144574 (92185–189056) 0.7
Soluble CD14 ng/ml 1066 (935–1365) 1043 (885–1281) 0.9
All patients were male, non smokers.
Medians (25th and 75th %tiles) were adjusted by age, hypertension, and duration of antiretroviral therapy using quantile regression.
*Significance determined using a two-tailed t-test based on estimated variance.
**Thresholds for biochemical markers were included in the summary statistic and calculated using the median between the commercial threshold given
and 0.
D – detectable; UD – undetectable; us-CRP – ultra-sensitive C-reactive protein; IL – interleukin; HMW – high molecular weight; ICAM-1 – intercellular
adhesion molecule-1; I-TAC – interferon inducible T-cell alpha chemoattractant; IP-10 – inducible protein-10; VCAM-1 – vascular cell adhesion molecule-1;
MCP-1 – monocyte chemoattractant protein-1.
doi:10.1371/journal.pone.0113876.t002
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differences between viremia groups: HDL- (D50.021 mm, p50.2) or LDL-
cholesterol (D50.022 mm, p50.2), statin-use (D50.019, p50.3), and family
history of CVD (D50.023, p50.18).
In contrast, a significant difference between groups was found in mean adjusted
cca-IMT (mean¡SE, D: 0.727 mm¡0.015 versus UD: 0.668 mm¡0.010,
p50.002), which remained independently associated with age and HOMA-IR.
This difference remained statistically significant after separately and additionally
Table 3. Total and common carotid artery intima media thicknesses between viremia groups.
Total c-IMT cca-IMT
Univariate Multivariable Univariate Multivariable
D* (95% CI) p D* (95% CI) p D* (95% CI) p D* (95% CI) p
D- vs UD-viremia groups 0.045 (0.002, 0.089) 0.04
0.021 (20.012,
0.055) 0.2 0.074 (0.026, 0.123) 0.003
0.059 (0.022,
0.095) 0.002
Cardiovascular risk-factors
Age (per 10 years) 0.077 (0.047, 0.106) ,0.001 0.061 (0.032,
0.089)
,0.001 0.077 (0.040, 0.114) ,0.001 0.048 (0.018,
0.078)
0.002
SBP (per 10 mmHg) 0.015 (0.000, 0.030) 0.06 0.020 (0.003, 0.038) 0.02 0.012 (20.002,
0.027)
0.09
Hypertension** 0.010 (0.020, 0.179) 0.02 0.166 (0.080, 0.252) ,0.001
HDL-cholesterol (per mmol/L) 20.046 (20.123,
0.031)
0.2 20.027 (20.117,
0.064)
0.6
LDL-cholesterol (per mmol/L) 0.027 (0.005, 0.048) 0.02 0.024 (20.002,
0.050)
0.07
Family history of CVD 0.000 (20.084,
0.086)
0.9 0.045 (20.053,
0.143)
0.4
HOMA-IR 0.036 (0.017, 0.055) 0.001 0.025 (0.009,
0.042)
0.003 0.051 (0.031, 0.072) ,0.001 0.034 (0.014,
0.053)
0.001
Statin-use 20.006 (20.091,
0.079)
0.9 0.061 (20.036,
0.159)
0.2
HIV-related factors
Nadir CD4+ (per 100 cells/
mm3)
20.004 (20.015,
0.007)
0.5 20.001 (20.014,
0.012)
0.9
CD4+ (per 100 cells/mm3) 0.004 (20.007,
0.015)
0.4 0.003 (20.010,
0.016)
0.7
Duration of ART (per year) 0.012 (0.005, 0.020) 0.002 0.007 (20.003,
0.017)
0.15
Yrs from last HIV VL .50 cp/
mL
20.001 (20.009,
0.006)
0.7 0.000 (20.009,
0.009)
0.9
PI-use 0.025 (20.016,
0.066)
0.2 0.020 (20.028,
0.068)
0.4
Abacavir-use 20.017 (20.063,
0.029)
0.5 20.023 (20.076,
0.031)
0.4
All patients were male, non smokers.
*Difference in intima media maximal thickness between groups.
**Hypertension was defined by prior physician‘s diagnosis or systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg.
c-IMT – carotid intima media thickness; cca-IMT – common carotid artery intima media thickness; D – detectable; UD – undetectable; SBP – systolic blood
pressure; HDL – high-density lipid; LDL – low-density lipid; CVD – cardiovascular disease; HOMA-IR – homeostatic model assessment of insulin resistance;
ART – antiretroviral therapy; VL – viral load; PI – protease inhibitors.
doi:10.1371/journal.pone.0113876.t003
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adjusting (to the full multivariable model) for years undergoing ART
(D50.059 mm, p50.003), years of known HIV-infection (D50.058 mm,
p50.003), years of undetectable HIV-viremia from most recent HIV-VL .50
copies/mL (D50.059 mm, p50.002), nadir CD4+ cell count (D50.059, p50.002)
and protease inhibitor (PI)-use (D50.060 mm, p50.002). The significant
association continued to remain after additionally adjusting for HDL-
(D50.057 mm, p50.003) or LDL-cholesterol (D50.058 mm, p50.003), statin-
use (D50.042, p50.04), and family history of CVD (D50.057, p50.004).
As shown in Table 4, only age was significantly associated with increased
bifurcation c-IMT, while no significant difference was observed between viremia
groups (mean¡SE, D: 0.840 mm¡0.024 versus UD: 0.841 mm¡0.016, p50.9).
Conversely, HIV-RNA viremia .1 copy/mL was the only significant variable
associated with differences in ica-IMT in multivariable analysis (mean¡SE, D:
0.758 mm¡0.019 versus UD: 0.707 mm¡0.012, p50.03).
Plaque prevalence and residual virema
Plaque prevalence tended to be higher in patients with respective D versus UD-
viremia (50.0% vs 24.2%, p50.1). As expected, plaque was mostly located on the
carotid bifurcation segment (n512) or on several sites (ica and bifurcation, n52;
cca and bifurcation, n51).
Discussion
In this highly-selected population, we report for the first time that residual
viremia was strongly associated with increased IMT on the common carotid artery
segment, broadening similar findings at higher HIV-RNA levels during ART [11]
and among patients displaying elite control of HIV-replication. [12, 13] When
examining the other carotid artery segments, we observed that HIV-VL between
1-20 copies was the only significant predictor of thicker internal carotid artery
IMT. Nevertheless, it was clear that IMT at the bifurcation segment, which is
known to be rather heterogeneous between individuals [14], showed the highest
variability of all IMT segments measured with high prevalence of plaque. This
could help explain why no difference in total c-IMT was observed between
viremia groups.
Furthermore, the magnitude of difference observed on the cca-IMT could be
considered clinically relevant. For instance, Ando et al. [15] reported in a large
cross-sectional study that an average increase in cca-IMT of 0.04–0.06 mm was
associated with a 10-year increase in age. Among younger HIV-infected patients,
mean cca-IMT was shown to be 0.04 mm higher in patients 40–47 compared to
24–35 years of age. [16] It would then appear that the difference of roughly
0.06 mm between viremia groups, even after adjusting for age, systolic blood
pressure, and HOMA-IR, falls in line with clinically important thresholds.
Interestingly, preliminary evidence has pointed to a roughly 4% increased
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absolute difference in prevalent 5-year mortality when comparing patients with 1–
19 copies/mL and ,1 copy/mL [6], suggesting a potential clinical association with
residual viremia. Naturally, these results need to be confirmed in larger
epidemiological studies.
Although a wide variety of biomarkers have produced strong associations with
higher levels of HIV-replication [6, 17, 18], several studies have failed to
demonstrate their significance at ,50 copies/mL. [3, 5] From our data, it is hard
to determine what role inflammation has on increased c-IMT. The generally
higher inflammatory levels observed in patients with detectable versus
undetectable HIV viremia indicates that the degree of systemic inflammation may
be slightly attenuated, compared to inflammation at higher HIV levels. Larger
populations would be needed to properly establish any meaningful difference.
Even so, the biological source of inflammation during persistent HIV-viremia
remains unclear, as evidence has reported a number of putative mechanisms
related to continual production of HIV-RNA from latent reservoirs. [1, 3, 19]
Table 4. Bifurcation and internal carotid artery intima media thicknesses between viremia groups.
Bifurcation IMT ica-IMT
Univariate Multivariable Univariate Multivariable
D* (95% CI) p D* (95% CI) p D* (95% CI) p D* (95% CI) p
D- vs UD-viremia groups 0.033 (20.036, 0.101) 0.3 20.001 (20.058, 0.059) 0.9 0.051(0.007, 0.096) 0.03 **
Cardiovascular risk-factors
Age (per 10 years) 0.110 (0.064, 0.157) ,0.001 0.111 (0.062, 0.159) ,0.001 0.032 (20.006, 0.069) 0.09
SBP (per 10 mmHg) 0.018 (20.005, 0.042) 0.13 20.005 (20.021, 0.011) 0.5
Hypertension*** 0.070 (20.057, 0.197) 0.3 0.062 (20.023, 0.146) 0.15
HDL-cholesterol (per mmol/L) 20.068 (20.185, 0.048) 0.2 20.036 (20.116, 0.043) 0.4
LDL-cholesterol (per mmol/L) 0.043 (0.011, 0.075) 0.01 0.013 (20.011, 0.036) 0.3
Family history of CVD 20.014 (20.143, 0.115) 0.8 20.044 (20.130, 0.041) 0.3
HOMA-IR 0.042 (0.011, 0.073) 0.009 0.005 (20.018, 0.027) 0.7
Statin-use 20.067 (20.194, 0.061) 0.3 20.022 (20.108, 0.065) 0.6
HIV-related factors
Nadir CD4+ (per 100 cells/mm3) 20.005 (20.022, 0.012) 0.5 20.004 (20.016, 0.007) 0.5
CD4+ (per 100 cells/mm3) 0.163 (20.260, 0.586) 0.4 0.080 (20.212, 0.371) 0.6
Duration of ART (per year) 0.020 (0.008, 0.031) 0.001 0.008 (0.000, 0.017) 0.046
Yrs from last HIV VL .50 cp/mL 20.003 (20.015, 0.008) 0.6 0.001 (20.007, 0.008) 0.9
PI-use 0.022 (20.041, 0.085) 0.5 0.028 (20.015, 0.071) 0.2
Abacavir-use 20.036 (20.106, 0.034) 0.3 0.008 (20.041, 0.057) 0.7
All patients were male, non smokers.
*Difference in intima media maximal thickness between groups.
**D-viremia was the only significant predictor. Adding duration of ART to the model did not improve model fit (difference in BIC: 0.616) and was hence not
included.
***Hypertension was defined by prior physician‘s diagnosis or systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg.
IMT – intima media thickness; ica-IMT – internal carotid artery intima media thickness; D – detectable; UD – undetectable; SBP – systolic blood pressure;
HDL – high-density lipid; LDL – low-density lipid; CVD – cardiovascular disease; HOMA-IR – homeostatic model assessment of insulin resistance; ART –
antiretroviral therapy; VL – viral load; PI – protease inhibitors.
doi:10.1371/journal.pone.0113876.t004
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No association with c-IMT and any specific antiretroviral treatment was noted
in our study, contrary to other epidemiological reports. [11, 12, 18] Our study
sample does have certain obvious differences compared to these studies in that the
patient numbers were much smaller and CVD-risk much lower, greatly affecting
the power necessary to establish a difference in c-IMT for any one treatment.
Nevertheless, future research should pay particular attention to some of the more
recent and commonly-used treatments. For example, treatment-experienced
patients with well-controlled HIV-RNA have shown substantial reductions in
inflammatory markers and markers of monocyte activation after switching to
ART containing the integrase inhibitor raltegravir (RAL). [20, 21] Whether these
results directly translate into changes in subclinical markers of atherosclerosis is
debatable, given that switching to RAL-based regimens failed to show
improvement in flow-mediated dilation. [22] Moreover, studies examining both
switching to and intensification of RAL-based ART have not demonstrated any
further decrease in ultrasensitive HIV-RNA detection [23, 24], leaving it difficult
to hypothesize how residual viremia would fit into the association between RAL
and inflammation.
One of the major limitations of our study was the few numbers of patients
included. We attempted to mitigate the impact of this problem by accounting for
two major classical CVD risk factors, smoking and gender, in the study design,
where otherwise large variability would have been introduced. As a result, IMT
levels were much lower than what has been previously reported among HIV-
infected subjects. Indeed, generalizability of our results was limited, yet with the
added advantage of increased validity.
Another limitation of our study was that we did not perform repeated
measurements of ultrasensitive HIV-RNA, since the aliquots of plasma required to
do so exceeded the available amount. Nevertheless, we examined ultrasensitive VL
12-months prior to study visit in a subset of patients (N537), showing a
proportion of patients with HIV-VL below detection threshold at both time
points (45.9%) that was roughly similar to a longitudinal study measuring
ultrasensitive HIV-RNA in quadruplicate. [3] Finally, outliers could account for
some of the differences observed. We repeated the analysis using robust linear
regression, which assigns a lower weight to values with higher absolute residuals,
to reconstruct the multivariable models, giving similar models with the same
conclusion with respect to all c-IMT segments (data not shown). Furthermore, we
employed a multivariable modeling strategy known to limit the number of
potential confounders, hence all models could only include a handful of
confounders at a time. Future research needs to establish how other CVD risk-
factors could play a role in the purported association between residual viremia
and increased IMT.
In conclusion, higher IMT in certain carotid artery segments was observed in
patients with residual viremia. This finding warrants larger longitudinal studies in
order to confirm our results and determine if changes in residual viremia are
correlated with changes in inflammatory markers and c-IMT.
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